Get the Stockscreener App
85.02
0.82%
0.69
Pre-market:
90.65
5.63
+6.62%
Structure Therapeutics Inc Adr stock is traded at $85.02, with a volume of 959.35K.
It is up +0.82% in the last 24 hours and up +31.20% over the past month.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
See More
Previous Close:
$84.33
Open:
$83.66
24h Volume:
959.35K
Relative Volume:
0.65
Market Cap:
$6.01B
Revenue:
-
Net Income/Loss:
$-100.44M
P/E Ratio:
-38.30
EPS:
-2.22
Net Cash Flow:
$-105.32M
1W Performance:
+26.93%
1M Performance:
+31.20%
6M Performance:
+342.12%
1Y Performance:
+216.18%
1-Day Range:
$80.85
$85.39
1-Week Range:
$66.59
$85.39
52-Week Range:
$13.22
$94.90
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
Name
Structure Therapeutics Inc Adr
Sector
Industry
Phone
(650) 457-1978
Address
601 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO
Compare GPCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
85.02 | 5.96B | 0 | -100.44M | -105.32M | -2.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.92 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.92 | 79.26B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
813.24 | 49.47B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.26 | 48.47B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.29 | 38.37B | 4.98B | 69.59M | 525.67M | 0.5197 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-02-25 | Initiated | Citigroup | Buy |
| Feb-28-25 | Initiated | William Blair | Outperform |
| Jan-08-25 | Initiated | Stifel | Buy |
| Dec-04-24 | Initiated | H.C. Wainwright | Buy |
| Sep-23-24 | Initiated | Morgan Stanley | Overweight |
| May-21-24 | Initiated | JP Morgan | Overweight |
| Apr-09-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-19-23 | Initiated | JMP Securities | Mkt Outperform |
| Jul-27-23 | Initiated | Piper Sandler | Overweight |
| May-25-23 | Resumed | Jefferies | Buy |
| Feb-28-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-28-23 | Initiated | Guggenheim | Buy |
| Feb-28-23 | Initiated | Jefferies | Buy |
| Feb-28-23 | Initiated | SVB Securities | Outperform |
View All
Structure Therapeutics Inc Adr Stock (GPCR) Latest News
Structure Therapeutics Inc. (GPCR) Has Gained Over 130% in 3 Months. Here is Why - Finviz
Structure Therapeutics CEO Stevens on Pipeline Strategy - Bloomberg
Structure Therapeutics Stock Surges Amid Positive Analyst Ratings - StocksToTrade
Janney Capital Management LLC Buys New Shares in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
A 10% Owner Of Structure Therapeutics Shed Shares - The Globe and Mail
Structure Therapeutics (NASDAQ:GPCR) Trading 12.2% HigherShould You Buy? - MarketBeat
A 10% Owner Of Structure Therapeutics Shed Shares - The Motley Fool
Price Target Hike Sparks Optimism for Structure Therapeutics - StocksToTrade
Why Structure Therapeutics Shares Are Surging Now - TipRanks
Assessing Structure Therapeutics (GPCR) Valuation After Obesity Trial Progress And Genentech Licensing Deal - Sahm
Structure Therapeutics inks major GLP-1 licensing deal - MSN
The Technical Signals Behind (GPCR) That Institutions Follow - Stock Traders Daily
Can This Stock Double Again in 2026? - Finviz
VKTX Completes Enrollment in Phase I Maintenance Study of Obesity Drug - sharewise.com
Genentech Licensing Deal For Oral Obesity Drug CT-996 Might Change The Case For Investing In Structure Therapeutics (GPCR) - Sahm
H.C. Wainwright Upgrades Structure Therapeutics (GPCR) on Massive Arbitrage Opportunity for Oral GLP-1 - Finviz
Why Structure Therapeutics Shares Are Surging Higher - TipRanks
Roche Clears Obesity Pill Legal Concerns With Structure Patent Agreement - BioSpace
Cantor Fitzgerald reiterates Structure Therapeutics stock rating at Overweight By Investing.com - Investing.com UK
Structure Therapeutics stock gets BMO Capital’s Outperform rating reaffirmed By Investing.com - Investing.com UK
Genentech makes $100M deal with South City neighbor to clear path for GLP-1 weight-loss drug - The Business Journals
Structure Therapeutics (NASDAQ:GPCR) Stock Price Down 6.4%What's Next? - MarketBeat
Voya Investment Management LLC Sells 14,230 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - Defense World
Analysts Are Bullish on These Healthcare Stocks: Palisade Bio (PALI), Centessa Pharmaceuticals (CNTA) - The Globe and Mail
Osaic Holdings Inc. Buys 31,972 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Medical Stocks To Watch TodayDecember 8th - MarketBeat
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Shares Down 3.3%Here's Why - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Stock Price Up 5.2%Here's Why - MarketBeat
Novo Nordisk Wins FDA Nod for Oral Wegovy in Obesity, Stock Up - Eastern Progress
What Awaits These 4 Biotech Stocks That More Than Doubled in 2025 - Finviz
Structure Therapeutics stock price target raised to $90 from $60 at H.C. Wainwright - Investing.com
Structure Therapeutics (NASDAQ:GPCR) Shares Gap Up – What’s Next? - Defense World
Avoiding Lag: Real-Time Signals in (GPCR) Movement - Stock Traders Daily
GPCRStructure Therapeutics Inc ADR Stock Price and Quote - Finviz
Structure Therapeutics (NASDAQ:GPCR) Shares Gap UpStill a Buy? - MarketBeat
Why Structure Therapeutics Shares Are Under Pressure Now - TipRanks
Pharmaceutical Stocks To Follow TodayDecember 8th - MarketBeat
Analysts Have Conflicting Sentiments on These Healthcare Companies: Novan (NOVN) and Pfizer (PFE) - The Globe and Mail
Structure Therapeutics begins phase 1 trial of oral obesity drug By Investing.com - Investing.com India
Structure Therapeutics begins phase 1 trial of oral obesity drug - Investing.com
New once-daily obesity pill enters first human tests using amylin biology - Stock Titan
Structure Therapeutics (NASDAQ:GPCR) Stock Price Down 8.5%Should You Sell? - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Price Target Raised to $120.00 - Defense World
Mid Cap Stocks To Watch TodayDecember 8th - MarketBeat
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Evommune, Inc. (EVMN) and Eli Lilly & Co (LLY) - The Globe and Mail
Bellevue Group AG Acquires 126,812 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Birchview Capital LP Buys Shares of 36,000 Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics, Inc. Sponsored ADR (GPCR) Receives a Buy from Morgan Stanley - The Globe and Mail
Structure Therapeutics stock price target raised to $120 by Citizens - Investing.com South Africa
Structure Therapeutics (NASDAQ:GPCR) Raised to Hold at Wall Street Zen - MarketBeat
Structure Therapeutics Inc Adr Stock (GPCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.67%
1.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):